Research Study

Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus
Principal Investigator 
David Maberley

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01295073
Status 
Recruiting
Study Start/End 
Jul 2, 2013 to Oct 24, 2017
Locations 
Vancouver General Hospital
Name/Title 
Theresa Wiens, Study Coordinator
Purpose of Study 

The primary purpose of the protocol is to evaluate whether Trientine Hydrochloride, a copper chelator which is an agent that binds with and removes copper, will be effective in minimizing macular edema after cataract surgery in individuals with type 2 diabetes. It is our hypothesis that there will be a reduction in copper-attributed inflammation after surgery resulting a decrease in edema.


 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.